{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:43Z","timestamp":1793291623010,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":192,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is a recent surge in interest in the application of artificial intelligence (AI) in prostate cancer (PCa). When evaluating PSMA PET scans, AI has shown promise in detecting intraprostatic cancer and metastatic disease. This systematic review aims to assess the ability of AI to detect or predict the progression of PCa during AS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review was registered on PROSPERO (ID CRD42024529354) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A comprehensive literature search was performed on Medline, Embase, Web of Science, and IEEE Xplore. Only studies evaluating AI in AS-eligible patients were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After screening 842 articles, 12 studies were suitable for inclusion. The included studies comprised of 4622 AS patients of whom 1022 experienced progressions. Only three studies utilised developed their AI purely on clinicopathological variables. The area under curve (AUC) of these three AI ranged between 0.65 and 0.76, and the AI algorithm in one study outperformed traditional logistic regression. The integration of MRI parameters particularly the use of radiomics improves the ability of AI to predict progression as compared to clinicopathological variables alone. AI was also able to analyse serial MRI during AS and performs on par with the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system. The AUC of the AI algorithms which included MRI parameters ranged between 0.65 and 0.95. One of the limitations was the variability in study methodologies and inclusion criteria. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was used and none of the studies had high risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AI shows promise in detecting PCa progression during AS. However, this systematic review highlights the need for larger prospective studies with external validation before AI can be integrated into the AS process.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01107-6","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:42:45Z","timestamp":1778589765000},"page":"916-926","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Exploring the utility of artificial intelligence in identifying progression of prostate cancer during active surveillance: A systematic review"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-2011","authenticated-orcid":false,"given":"Jianliang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dixon T. S.","family":"Woon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafy","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Cundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilakavathi","family":"Chengodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanadakishor","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marimuthu","family":"Palaniswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1138-6389","authenticated-orcid":false,"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8553-5618","authenticated-orcid":false,"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"1107_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"1107_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.euo.2023.10.005","volume":"7","author":"HV Stroomberg","year":"2024","unstructured":"Stroomberg HV, Larsen SB, Kj\u00e6r Nielsen T, Helgstrand JT, Brasso K, R\u00f8der A. Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population. Eur Urol Oncol. 2024;7:770\u20137.","journal-title":"Eur Urol Oncol"},{"key":"1107_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148\u201363.","journal-title":"Eur Urol"},{"key":"1107_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/JU.0000000000002758","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022;208:19\u201325.","journal-title":"J Urol"},{"key":"1107_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21:1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"key":"1107_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2018.10.025","volume":"75","author":"M Van Hemelrijck","year":"2019","unstructured":"Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, et al. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. Eur Urol. 2019;75:523\u201331.","journal-title":"Eur Urol"},{"key":"1107_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/MOU.0000000000000158","volume":"25","author":"L Klotz","year":"2015","unstructured":"Klotz L. Defining \u2018progression\u2019 and triggers for curative intervention during active surveillance. Curr Opin Urol. 2015;25:258\u201366.","journal-title":"Curr Opin Urol"},{"key":"1107_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41391-018-0075-4","volume":"22","author":"NJ Sathianathen","year":"2019","unstructured":"Sathianathen NJ, Butaney M, Bongiorno C, Konety BR, Bolton DM, Lawrentschuk N. Accuracy of the magnetic resonance imaging pathway in the detection of prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2019;22:39\u201348.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1107_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","volume":"80","author":"P Rajwa","year":"2021","unstructured":"Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, et al. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis. Eur Urol. 2021;80:549\u201363.","journal-title":"Eur Urol"},{"key":"1107_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.rcl.2017.10.013","volume":"56","author":"B Turkbey","year":"2018","unstructured":"Turkbey B, Choyke PL. Future Perspectives and Challenges of Prostate MR Imaging. Radio Clin North Am. 2018;56:327\u201337.","journal-title":"Radio Clin North Am"},{"key":"1107_CR11","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","volume":"71","author":"CM Moore","year":"2017","unstructured":"Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, et al. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations\u2014A Report of a European School of Oncology Task Force. Eur Urol. 2017;71:648\u201355.","journal-title":"Eur Urol"},{"key":"1107_CR12","doi-asserted-by":"crossref","unstructured":"Englman C, Maffei D, Allen C, Kirkham A, Albertsen P, Kasivisvanathan V, et al. PRECISE Version 2: Updated Recommendations for Reporting Prostate Magnetic Resonance Imaging in Patients on Active Surveillance for Prostate Cancer. Eur Urol. 2024;86:240\u201355.","DOI":"10.1016\/S0302-2838(24)01391-5"},{"key":"1107_CR13","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.eururo.2021.01.016","volume":"79","author":"F Giganti","year":"2021","unstructured":"Giganti F, Kasivisvanathan V, Allen C, Moore CM. The Importance of Being PRECISE in Prostate Magnetic Resonance Imaging and Active Surveillance. Eur Urol. 2021;79:560\u20133.","journal-title":"Eur Urol"},{"key":"1107_CR14","doi-asserted-by":"publisher","unstructured":"Bohr A, Memarzadeh K. The rise of artificial intelligence in healthcare applications. Artif Intell Healthcare. 2020:25\u201360. https:\/\/doi.org\/10.1016\/B978-0-12-818438-7.00002-2.","DOI":"10.1016\/B978-0-12-818438-7.00002-2"},{"key":"1107_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41591-021-01614-0","volume":"28","author":"P Rajpurkar","year":"2022","unstructured":"Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28:31\u20138.","journal-title":"Nat Med"},{"key":"1107_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MOU.0000000000001144","volume":"34","author":"DG Gelikman","year":"2024","unstructured":"Gelikman DG, Rais-Bahrami S, Pinto PA, Turkbey B. AI-powered radiomics: revolutionizing detection of urologic malignancies. Curr Opin Urol. 2024;34:1\u20137.","journal-title":"Curr Opin Urol"},{"key":"1107_CR17","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","volume":"44","author":"G van Leenders","year":"2020","unstructured":"van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87\u2013e99.","journal-title":"Am J Surg Pathol"},{"key":"1107_CR18","first-page":"14","volume":"9","author":"RY Choi","year":"2020","unstructured":"Choi RY, Coyner AS, Kalpathy-Cramer J, Chiang MF, Campbell JP. Introduction to Machine Learning, Neural Networks, and Deep Learning. Transl Vis Sci Technol. 2020;9:14.","journal-title":"Transl Vis Sci Technol"},{"key":"1107_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M18-1376","volume":"170","author":"RF Wolff","year":"2019","unstructured":"Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies. Ann Intern Med. 2019;170:51\u20138.","journal-title":"Ann Intern Med"},{"key":"1107_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.euf.2021.07.004","volume":"7","author":"JCC Kwong","year":"2021","unstructured":"Kwong JCC, McLoughlin LC, Haider M, Goldenberg MG, Erdman L, Rickard M, et al. Standardized Reporting of Machine Learning Applications in Urology: The STREAM-URO Framework. Eur Urol Focus. 2021;7:672\u201382.","journal-title":"Eur Urol Focus"},{"key":"1107_CR21","doi-asserted-by":"crossref","unstructured":"Chandramouli S, Leo P, Lee G, Elliott R, Davis C, Zhu G, et al. Computer Extracted Features from Initial H&E Tissue Biopsies Predict Disease Progression for Prostate Cancer Patients on Active Surveillance. Cancers (Basel). 2020;12:2708.","DOI":"10.3390\/cancers12092708"},{"key":"1107_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.euros.2023.04.002","volume":"52","author":"N Sushentsev","year":"2023","unstructured":"Sushentsev N, Abrego L, Colarieti A, Sanmugalingam N, Stanzione A, Zawaideh JP, et al. Using a Recurrent Neural Network To Inform the Use of Prostate-specific Antigen (PSA) and PSA Density for Dynamic Monitoring of the Risk of Prostate Cancer Progression on Active Surveillance. Eur Urol Open Sci. 2023;52:36\u20139.","journal-title":"Eur Urol Open Sci"},{"key":"1107_CR23","doi-asserted-by":"publisher","first-page":"161.e1","DOI":"10.1016\/j.urolonc.2021.08.007","volume":"40","author":"M Nayan","year":"2022","unstructured":"Nayan M, Salari K, Bozzo A, Ganglberger W, Lu G, Carvalho F, et al. A machine learning approach to predict progression on active surveillance for prostate cancer. Urol Oncol. 2022;40:161.e1\u2013.e7.","journal-title":"Urol Oncol"},{"key":"1107_CR24","doi-asserted-by":"publisher","first-page":"191.e15","DOI":"10.1016\/j.urolonc.2022.01.012","volume":"40","author":"B ElKarami","year":"2022","unstructured":"ElKarami B, Deebajah M, Polk S, Peabody J, Shahrrava B, Menon M, et al. Machine learning-based prediction of upgrading on magnetic resonance imaging targeted biopsy in patients eligible for active surveillance. Urol Oncol. 2022;40:191.e15\u2013.e20.","journal-title":"Urol Oncol"},{"key":"1107_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92341-6","volume":"11","author":"N Sushentsev","year":"2021","unstructured":"Sushentsev N, Rundo L, Blyuss O, Gnanapragasam VJ, Sala E, Barrett T. MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. Sci Rep. 2021;11:12917.","journal-title":"Sci Rep"},{"key":"1107_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/pros.24528","volume":"83","author":"B Oerther","year":"2023","unstructured":"Oerther B, Engel H, Nedelcu A, Schlett CL, Grimm R, von Busch H, et al. Prediction of upgrade to clinically significant prostate cancer in patients under active surveillance: Performance of a fully automated AI-algorithm for lesion detection and classification. Prostate. 2023;83:871\u20138.","journal-title":"Prostate"},{"key":"1107_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.604266","volume":"10","author":"J Xie","year":"2020","unstructured":"Xie J, Li B, Min X, Zhang P, Fan C, Li Q, et al. Prediction of Pathological Upgrading at Radical Prostatectomy in Prostate Cancer Eligible for Active Surveillance: A Texture Features and Machine Learning-Based Analysis of Apparent Diffusion Coefficient Maps. Front Oncol. 2020;10:604266.","journal-title":"Front Oncol"},{"key":"1107_CR28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s00330-021-08151-x","volume":"32","author":"N Sushentsev","year":"2022","unstructured":"Sushentsev N, Rundo L, Blyuss O, Nazarenko T, Suvorov A, Gnanapragasam VJ, et al. Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol. 2022;32:680\u20139.","journal-title":"Eur Radiol"},{"key":"1107_CR29","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1007\/s00330-023-09438-x","volume":"33","author":"N Sushentsev","year":"2023","unstructured":"Sushentsev N, Rundo L, Abrego L, Li Z, Nazarenko T, Warren AY, et al. Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. Eur Radiol. 2023;33:3792\u2013800.","journal-title":"Eur Radiol"},{"key":"1107_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-022-00659-w","volume":"5","author":"C Lee","year":"2022","unstructured":"Lee C, Light A, Saveliev ES, van der Schaar M, Gnanapragasam VJ. Developing machine learning algorithms for dynamic estimation of progression during active surveillance for prostate cancer. NPJ Digital Med. 2022;5:110.","journal-title":"NPJ Digital Med"},{"key":"1107_CR31","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1007\/s00330-020-07008-z","volume":"30","author":"M Arif","year":"2020","unstructured":"Arif M, Schoots IG, Castillo Tovar J, Bangma CH, Krestin GP, Roobol MJ, et al. Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI. Eur Radiol. 2020;30:6582\u201392.","journal-title":"Eur Radiol"},{"key":"1107_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00330-022-09032-7","volume":"33","author":"C Roest","year":"2023","unstructured":"Roest C, Kwee TC, Saha A, F\u00fctterer JJ, Yakar D, Huisman H. AI-assisted biparametric MRI surveillance of prostate cancer: feasibility study. Eur Radiol. 2023;33:89\u201396.","journal-title":"Eur Radiol"},{"key":"1107_CR33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/cncr.35190","volume":"130","author":"J Xu","year":"2024","unstructured":"Xu J, Bock CH, Janisse J, Woo J, Cher ML, Ginsburg K, et al. Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS). Cancer. 2024;130:1797\u2013806.","journal-title":"Cancer"},{"key":"1107_CR34","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer. JAMA. 1998;280:969\u201374.","journal-title":"JAMA"},{"key":"1107_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","volume":"5","author":"M Baboudjian","year":"2022","unstructured":"Baboudjian M, Breda A, Rajwa P, Gallioli A, Gondran-Tellier B, Sanguedolce F, et al. Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression. Eur Urol Oncol. 2022;5:617\u201327.","journal-title":"Eur Urol Oncol"},{"key":"1107_CR36","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/bju.14554","volume":"123","author":"DR Kaye","year":"2019","unstructured":"Kaye DR, Qi J, Morgan TM, Linsell S, Ginsburg KB, Lane BR, et al. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU Int. 2019;123:846\u201353.","journal-title":"BJU Int"},{"key":"1107_CR37","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.imed.2023.08.001","volume":"4","author":"H Xu","year":"2024","unstructured":"Xu H, Shuttleworth KMJ. Medical artificial intelligence and the black box problem: a view based on the ethical principle of \u201cdo no harm. Intell Med. 2024;4:52\u20137.","journal-title":"Intell Med"},{"key":"1107_CR38","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41391-023-00705-y","volume":"27","author":"A Cocci","year":"2024","unstructured":"Cocci A, Pezzoli M, Lo Re M, Russo GI, Asmundo MG, Fode M, et al. Quality of information and appropriateness of ChatGPT outputs for urology patients. Prostate Cancer Prostatic Dis. 2024;27:103\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1107_CR39","doi-asserted-by":"crossref","unstructured":"Hershenhouse JS, Mokhtar D, Eppler MB, Rodler S, Storino Ramacciotti L, Ganjavi C, et al. Accuracy, readability, and understandability of large language models for prostate cancer information to the public. Prostate Cancer Prostatic Diseases. 2025;28:394\u20139.","DOI":"10.1038\/s41391-024-00826-y"},{"key":"1107_CR40","doi-asserted-by":"crossref","unstructured":"Lombardo R, Gallo G, Stira J, Turchi B, Santoro G, Riolo S, et al. Quality of information and appropriateness of Open AI outputs for prostate cancer. Prostate Cancer and Prostatic Diseases. 2025;28:229\u201331.","DOI":"10.1038\/s41391-024-00789-0"},{"key":"1107_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bju.16214","volume":"133","author":"D Bagguley","year":"2024","unstructured":"Bagguley D, Harewood L, McKenzie D, Ptasznik G, Ong S, Chengodu T, et al. The CONFIRM trial protocol: the utility of prostate-specific membrane antigen positron emission tomography\/computed tomography in active surveillance for prostate cancer. BJU Int. 2024;133:27\u201336.","journal-title":"BJU Int"},{"key":"1107_CR42","doi-asserted-by":"crossref","unstructured":"Liu J, Santucci J, Woon DTS, Catterwell R, Perera M, Murphy DG, et al. A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance? Life (Basel). 2024;14:76.","DOI":"10.3390\/life14010076"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01107-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01107-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:37Z","timestamp":1793289817000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01107-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01107-6","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}